Immunologic Factors: all 3,292 studies that test it

Page 27 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.

• A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple MyelomaCompletedNCT00915408Phase 1/2
• Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV TreatmentCompletedNCT00909129Not applicable
• The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00909077Phase 3
• Open Label Pilot Trial of Rituximab in Lupus Membranous NephritisWithdrawnNCT00908986Not applicable
• Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic PurpuraCompletedNCT00907751Phase 2
• Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal FailureStatus unknownNCT00902915Phase 2
• Lenalidomide and R-CHOP in B-cell LymphomaCompletedNCT00901615Phase 1/2
• Impact of the 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) on Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Jordanian InfantsStatus unknownNCT00900978Phase 1/2
• GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin LymphomaStatus unknownNCT00896519Phase 2
• GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaStatus unknownNCT00893477Phase 2
• Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic LeukemiaStatus unknownNCT00892827Phase 2
• Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated CardiomyopathyCompletedNCT00892112Phase 3
• Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple MyelomaCompletedNCT00891384Phase 3
• Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.CompletedNCT00890500Phase 1
• Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AMLStatus unknownNCT00887042Phase 1/2
• Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)CompletedNCT00885833Phase 1/2
• 7-valent Pneumococcal Conjugated VaccinationStatus unknownNCT00885625Phase 4
• A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qStatus unknownNCT00885508Phase 2
• A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) AmyloidosisCompletedNCT00883623Phase 2
• Tandem Stem Cell Transplantation for Non-Hodgkin's LymphomaActive, not recruitingNCT00882895Phase 2
• Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)Status unknownNCT00882323Phase 2
• Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to TreatmentWithdrawnNCT00881387Phase 2
• Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell TransplantCompletedNCT00880815Phase 1
• Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasActive, not recruitingNCT00877214Phase 3
• The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) AbnormalityCompletedNCT00874978Phase 2
• Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00868413Phase 1
• Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)CompletedNCT00864942Phase 1
• Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With RituximabStatus unknownNCT00863187Not applicable
• Comparison of ATG to Thymoglobuline in Renal TransplantationCompletedNCT00861536Phase 4
• Rituximab for Pulmonary SarcoidosisCompletedNCT00855205Phase 2
• Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)CompletedNCT00854139Phase 1
• Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic PainStatus unknownNCT00850005Phase 2
• Drug Intervention in Chronic Fatigue SyndromeCompletedNCT00848692Phase 2/3
• Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT00848328Phase 2
• Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple MyelomaCompletedNCT00847639Phase 2
• Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To TreatmentWithdrawnNCT00845104Phase 2
• Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 YearsStatus unknownNCT00843895Not applicable
• Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive LymphomasCompletedNCT00842595Phase 2
• Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00840931Phase 1
• Lenalidomide In Patients With Acute Myeloid LeukemiaTerminatedNCT00839059Phase 1
• The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular CarcinomaWithdrawnNCT00838968Not applicable
• Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell TransplantWithdrawnNCT00833534Phase 2
• Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms MacroglobulinemiaCompletedNCT00832234Phase 2
• A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201TerminatedNCT00831649Phase 2
• Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00831597Phase 2
• A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic LeukemiaWithdrawnNCT00829647Phase 1/2
• Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentWithdrawnNCT00829205Phase 1/2
• Lenalidomide and Decitabine in High Grade Myelodysplastic SyndromesCompletedNCT00828802Phase 1
• CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7CompletedNCT00812669Phase 2
• Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.CompletedNCT00809822Phase 2
• Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe PsoriasisCompletedNCT00808223Phase 2
• Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α TherapyWithdrawnNCT00801125Phase 4
• A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARLCompletedNCT00799136Phase 2
• Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in AdultsStatus unknownNCT00797810Phase 4
• Safety and Tolerability of Repeat Courses of IM AlefaceptCompletedNCT00794807Phase 4
• A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's LymphomaCompletedNCT00794638Phase 1
• Haploidentical Stem Cell Transplantation in NeuroblastomaStatus unknownNCT00790413Early Phase 1
• Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersCompletedNCT00788684Phase 1
• R-CHOP-B Bevacizumab for Diffuse Large B Cell LymphomaTerminatedNCT00788606Phase 2
• Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00787969Phase 1
• Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT00786851Phase 2
• Allo-hNHL (FluBuCy)CompletedNCT00785330Phase 2
• Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With PemphigusCompletedNCT00784589Phase 3
• Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV SubcutaneouslyCompletedNCT00782106Phase 1/2
• Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal FunctionCompletedNCT00779922Phase 2
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid ArthritisTerminatedNCT00779220Phase 2
• Dose-finding of Lenalidomide as Maintenance in Multiple MyelomaCompletedNCT00778752Phase 1/2
• Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia GravisCompletedNCT00774462Phase 2
• Zevalin® First Line in Follicular LymphomaStatus unknownNCT00772655Phase 2
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnNCT00771043Phase 4
• Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5CompletedNCT00761449Phase 2
• Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT00758693Phase 2
• Rescue of Steroidogenic Capacity in Adrenocortical Failure Study (RADS)CompletedNCT00753597Phase 4
• Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT00750126Phase 2
• Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasCompletedNCT00749112Phase 2/3
• Efficacy Study of Two Treatments in the Remission of VasculitisCompletedNCT00748644Phase 3
• A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady StateCompletedNCT00744679Phase 4
• Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDSCompletedNCT00744536Phase 2
• Tolerance and Efficacy of Rituximab in Sjogren's DiseaseCompletedNCT00740948Phase 2/3
• Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell LymphomaCompletedNCT00740415Phase 2
• Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLLCompletedNCT00738829Phase 1/2
• Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)Status unknownNCT00737685Phase 2
• Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00735930Phase 1
• Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) DonorStatus unknownNCT00733733Phase 3
• RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple MyelomaCompletedNCT00729638Phase 1
• Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00729118Phase 1
• Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin LymphomaCompletedNCT00726700Phase 2
• S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom MacroglobulinemiaWithdrawnNCT00723658Phase 2
• Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent MiscarriageCompletedNCT00722475Phase 3
• Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)TerminatedNCT00720850Phase 2
• Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaCompletedNCT00720135Phase 1
• Autologous Stem Cell Transplant for Neurologic Autoimmune DiseasesActive, not recruitingNCT00716066Phase 2
• Thymoglobulin: Presence and Affect in the Central Lymphatic CompartmentCompletedNCT00714480Not applicable
• Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant RecipientsWithdrawnNCT00709293Not applicable
• Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization ProtocolStatus unknownNCT00706680Phase 4
• Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell LymphomasTerminatedNCT00704691Early Phase 1
• Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in MyelomaCompletedNCT00698776Phase 1
• Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell TransplantCompletedNCT00697684Phase 1
• A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative ColitisCompletedNCT00694980Phase 1
• Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque PsoriasisCompletedNCT00692172Phase 3

← Immunologic Factors overview